Abstract: Posttraumatic stress disorder is a serious and often disabling syndrome that develops in response to a traumatic event. Many individuals who initially develop the disorder go on to experience a chronic form of the condition that in some cases can last for many years. Among these patients, psychiatric and medical comorbidities are common, including early onset of age-related conditions such as chronic pain, cardiometabolic disease, neurocognitive disorders, and dementia. The hallmark symptoms of posttraumatic stress-recurrent sensory-memory reexperiencing of the trauma(s)-are associated with concomitant activations of threat-and stress-related neurobiological pathways that occur against a tonic backdrop of sleep disturbance and heightened physiological arousal. Emerging evidence suggests that the molecular consequences of this stress-perpetuating syndrome include elevated systemic levels of oxidative stress and inflammation. In this article we review evidence for the involvement of oxidative stress and inflammation in chronic PTSD and the neurobiological consequences of these processes, including accelerated cellular aging and neuroprogression. Our aim is to update and expand upon previous reviews of this rapidly developing literature and to discuss magnetic resonance spectroscopy as an imaging technology uniquely suited to measuring oxidative stress and inflammatory markers in vivo. Finally, we highlight future directions for research and avenues for the development of novel therapeutics targeting oxidative stress and inflammation in patients with PTSD.
P osttraumatic stress disorder is a serious and often disabling condition that affects approximately 8% of individuals in the general population at some point during their lifetimes. 1 Estimates suggest that as many as one-third of those who develop PTSD go on to experience a chronic form of the disorder that, in many cases, lasts for years. 2, 3 Among those patients, psychiatric and medical comorbidities are common, with many presenting with early onset of age-related conditions such as cardiometabolic disease, 4 neurocognitive disorders, 5 and dementia. 6 The hallmark features of PTSD are recurrent sensorymemory episodes of reexperiencing the trauma(s), which can be spontaneous or cued by exposure to stimuli reminiscent of the trauma, anniversaries of the event, or other adverse life events. These episodes are accompanied by phasic activations of stress-related neurobiology that occur in the context of tonic symptoms of hypervigilance, heightened negative affect, and arousal. Together, these symptoms constitute a stress-perpetuating syndrome that maintains the individual in a chronic state of sustained stress. 7, 8 Emerging evidence suggests that the biological consequences of this condition may include elevated systemic levels of oxidative stress (OXS) and inflammation (INF), accelerated cellular aging, and neuroprogression-the pathological remodeling of neural circuitry that occurs over the course of a chronic mental illness.
The purpose of this article is to provide a qualitative review of the scientific literature on the relationship of PTSD to OXS and INF, and to discuss magnetic resonance spectroscopy (MRS) as a neuroimaging approach that is uniquely suited to studying the processes in vivo. The studies we reviewed were identified through a search of the PUBMED database spanning the years 1980 (the date of the first appearance of PTSD in DSM-III) through early 2017 using the following search terms: PTSD and [oxidative stress] (40 hits), PTSD and inflammation (163 hits), and PTSD and [magnetic resonance spectroscopy] (61 hits). We also examined the citations contained in the articles identified through this search. We did not access unpublished studies or include published abstracts. Our specific aims are to (1) update and expand upon our previous review of this rapidly developing topic, 7 with a new emphasis on the involvement of inflammatory processes, (2) provide a qualitative summary of studies that have examined associations between PTSD and biomarkers of OXS and INF, and (3) offer a review and summary of published MRS studies of PTSD. Finally, we highlight directions for future research and avenues for the development of novel therapeutics targeting OXS and INF in patients with PTSD.
MECHANISMS AND EFFECTS OF OXS AND INF
OXS is a cellular status that occurs when pro-oxidant molecules (e.g., reactive oxygen/nitrogen species [ROS/NOS]) exceed the capacity of available antioxidants (e.g., glutathione [GSH] , superoxide dismutase [SOD] , and related enzymes) to counteract their effects. Under acute OXS, antioxidants increase in response to the presence of pro-oxidant molecules. When OXS is prolonged, antioxidants become depleted, leading to cell degeneration and apoptosis. 9 OXS is a molecular mechanism fundamental to aging and widely implicated in many common diseases. The brain is particularly vulnerable to its deleterious effects due to its high metabolic demand and dense composition of oxidation-susceptible lipid cells. Studies have linked OXS to blood-brain barrier disruptions, altered patterns of neural growth, and changes in brain morphology. 10, 11 INF is a similarly ubiquitous cellular reaction implicated in many common diseases and initiated by cell injury. Its primary function is to destroy injurious agents or to protect injured tissue though the proliferation of inflammatory cells such as neutrophils, monocytes, and lymphocytes. At the site of INF, these cells trigger the release of various enzymes -including ROS/NOS, proinflammatory cytokines, and other chemical mediators-and, in doing so, induce OXS. Thus, OXS and INF tend to co-occur and are intertwined in such a way that one process can readily induce the other, and vice versa. 12 Emerging evidence suggests that both conditions can be triggered by chronic psychological stress or stress-related mental illnesses, including PTSD, and that their separate and interactive effects, when chronic, may exert destructive effects on the brain and peripheral organ systems.
OXIDATIVE STRESS and PTSD
Preliminary clinical evidence for the involvement of OXS in the pathophysiology of PTSD comes from cross-sectional studies that have found significant differences in blood antioxidant enzyme concentrations and OXS-related gene expression between PTSD patients and controls (see Table 1 ). For example, Atli and colleagues 21 reported elevated levels of serum lipid peroxidation (reflecting the breakdown and oxidation of polyunsaturated fatty acids) and depleted antioxidant enzymes in earthquake survivors with PTSD compared to earthquake-exposed controls. Similarly, Stefanovic and colleagues 20 measured blood levels of SOD and glutathione transferase in Croatian war veterans and found depleted levels of both antioxidants in veterans with PTSD compared to controls. Gene expression studies have found similar alterations in antioxidant gene RNA transcription in patients with PTSD. For example, Zieker and colleagues 15 observed downregulated expression of the antioxidant genes SOD and TXR1 (the latter of which produces thioredoxin reductase, which interacts with GSH to detoxify ROS) in patients with PTSD who witnessed a catastrophic air show disaster. In conjunction with these effects, Zieker and colleagues reported that transcripts for the proinflammatory cytokines genes interleukin (IL)-16 and -18 were downregulated, suggesting that the patients were immunocompromised as well. Several studies point to the presence of depleted levels of glutathione transferases (which interact with GSH to detoxify pro-oxidant molecules) in the pathophysiology of PTSD. For example, in one of the few longitudinal studies on this topic, Glatt and colleagues 17 reported that levels of glutathione S-transferase mu 1(GSTM1) measured prior to deployment predicted the subsequent development of PTSD symptoms in U.S. marines deployed to Iraq or Afghanistan. Subsequently, in a follow-up study based on the same cohort, Tylee and colleagues 18 showed that PTSD diagnostic status could be predicted with 80% accuracy using an algorithm based entirely on the expression of GSTM1 and its counterpart GSTM2.
Findings from studies of patients with depression and other anxiety disorders suggest a similar pattern. Specifically, studies have found depression to be associated with oxidative damage to DNA and suppressed antioxidant activity. 23, 24 Similarly, studies of patients with anxiety disorders have shown elevated levels of lipid peroxidation in generalized anxiety disorder 25 and suppressed antioxidant activity in panic disorder. 26 Indirect evidence also pointing to the possible involvement of OXS-related biology in PTSD came from the first genomewide association study (GWAS) of PTSD. 27 In that study, Logue and colleagues 27 found a genome-wide significant association between a single-nucleotide polymorphism (SNP), rs8042149, in the retinoic acid orphan receptor alpha gene (RORA) and a diagnosis of PTSD among veterans. Though subsequent PTSD GWASs have not replicated this association at GWAS-significant levels, one independent research group published a replication of the rs8042149-PTSD association, 28 and Miller and colleagues 29 found that another RORA SNP, rs17303244, was significantly associated with the severity of symptoms in the fear spectrum of psychopathology (as defined by panic, agoraphobia, specific phobia, and obsessivecompulsive disorder). Similarly, Lowe and colleagues 30 reported an association between RORA SNP rs893290 and PTSD symptom trajectories over time.
RORA is expressed in the prefrontal cortex, hippocampus, and hypothalamus. It is activated during OXS and serves to protect neurons by increasing the expression of other genes (Gpx1 and Prx6) involved in the clearance of ROS. Based on this, Miller and colleagues 29 hypothesized that individuals carrying RORA risk variant(s) may mount an inadequate response to OXS, placing them at risk for neurodegeneration and functional abnormalities in regions of the brain involved in modulating fear and anxiety. Other evidence pointing to the role of OXS in the neurobiology of PTSD came from a recent study that examined ALOX12 and ALOX15 in relationship to PTSD and measures of neural integrity. 8 The enzyme 12/15-lipoxygenase, transcribed by ALOX12 and ALOX15, is involved in mechanisms of oxidative damage to the brain. Specifically, when levels of GSH become depleted during OXS, 12/15-LOX attacks mitochondria and produces pro-oxidant reactive oxygen species. Given that characteristic, this enzyme has been referred to as "the central executioner in an OXS-related neuronal death program." 31(p 882) In other words, the available evidence suggests that 12/15-LOX serves as a key mediator of OXS-related neurodegeneration and could potentially be a future target for biomarker or treatment development. Based on that reasoning, Miller and colleagues 8 tested the hypothesis that genetic variants within ALOX12 or ALOX15 would moderate the association between PTSD and cortical thickness. Analyses identified a novel ALOX12 locus (rs1042357/rs10852889) that interacted with maximum lifetime PTSD severity to predict reduced thickness of the right prefrontal cortex, with this effect explaining 7% of the variance of cortical thickness in that region. Collectively, these findings point to the involvement of OXS in the pathophysiology of PTSD and underscore the role of individual differences in OXS resistance in conferring resilience/vulnerability to traumatic stress.
INFLAMMATION AND PTSD
Findings from blood biomarker, genetic association, and DNA methylation studies also point to the role of inflammatory processes in the pathophysiology of PTSD. A recent meta-analysis of plasma and serum studies incorporating the results of 20 such studies found the diagnosis to be reliably associated with elevated levels of circulating peripheral IL-6, IL-1β, TNFα, and interferon ϒ. 32 Genetic association studies have also implicated inflammation-related genes in the etiology of PTSD, and a recent network analysis of 83 candidate genes previously associated with the disorder showed that genes involved in INF, including TNFα and IL-1b, were also involved in regulating the PTSD-associated genes. 33 Similarly, differential DNA methylation (DNAm) or differential gene expression has been reported for INF and immune system genes in several PTSD studies. 15, 34, 35 One of the most widely studied and extensively validated markers of INF is C-reactive protein (CRP), a protein that can be measured in plasma or serum that responds to inflammatory stimuli by triggering cellular responses that lead to their clearance. CRP is the most sensitive of the body's inflammatory reactants and capable of proliferating up to 1000-fold in response to triggering stimuli. Because CRP is produced primarily in the liver, it was long assumed to be expressed solely in the periphery. Recent studies, however, have documented the presence of CRP in stroke lesions 36 and in cortical and subcortical tissue from patients with various neurodegenerative diseases. 37, 38 Emerging evidence also suggests that CRP is produced in microvessel endothelial cells that form the blood-brain barrier 39 and that peripheral CRP can affect the central nervous system via blood-brain barrier disruption. 40, 41 Studies of blood CRP levels in PTSD patients have yielded mixed results. Passos and colleagues 32 (2015) metaanalyzed results of five studies (131 cases; 136 controls total) but found no significant differences between cases and controls. However, several larger and more recent studies that were not included in that analysis have reported positive associations between PTSD symptom severity and plasma CRP levels (see Table 2 ), but again, not all additional findings have been uniform (cf. Baumert ). One often cited, but as yet understudied, source of variability in findings across studies is unmeasured genetic variation in relevant genes such as CRP. Twin studies of blood CRP levels have estimated its heritability to be between 25% and 40%, [59] [60] [61] and large-scale GWAS studies with n's >10,000 have found individual CRP polymorphisms to be associated with up to 64% differences in blood CRP levels (e.g., rs3091244 AA versus CC genotype 62 ). To our knowledge, however, only one published study has examined the association of CRP genetic variation with CRP levels and PTSD. In that study, Michopoulos and colleagues 56 found CRP SNP rs1130864 to be significantly associated with PTSD symptom severity in their full sample (n = 2692) and with plasma CRP levels in a subsample (n = 137). 56 Plasma CRP was also positively correlated with impaired inhibition to a safety cue in the context of a fear-potentiated startle study (n = 135), suggesting a link between inflammatory status and fear circuitry.
POSSIBLE MECHANISMS FOR THE ASSOCIATION BETWEEN PTSD, ELEVATED OXIDATIVE STRESS, AND INFLAMMATION
One possible mechanism for the associations between PTSD, OXS, and INF is via chronic and repeated activation of the hypothalamic-pituitary-adrenal (HPA) axis, which occurs during reexperiencing the trauma. Such activation has been identified as a primary mechanism of stress-related damage to the brain. Specifically, the glucocorticoid-hippocampal atrophy model 63 posits that stress-induced glucocorticoids exert neurotoxic effects on the brain, especially on regions with a high density of glucocorticoid receptors such as the hippocampus and prefrontal cortex.
Animal studies have found evidence consistent with a causal association between elevated glucocorticoids and increased levels of ROS and markers of oxidative damage. 64 In a meta-analysis of 19 studies, Costantini and colleagues 65 found a mean effect size of r = 0.55 for the effect of glucocorticoid administration on OXS parameters and also found an association between the duration of glucocorticoid administration and extent of oxidative damage. Another study showed that subcutaneous corticosterone administration was associated with increased oxidation and reduced antioxidant enzyme activity in the rat hippocampus. 66 Furthermore, paralleling results of clinical neuroimaging studies of PTSD, these effects were linked to hippocampal cell death and memory impairment on a learning task.
The HPA axis is also reciprocally coupled with the immune system. 64, 67 Glucocorticoids generally restrict the inflammatory process by inhibiting synthesis and release of proinflammatory cytokines, 68 but under conditions of excitotoxicity, elevated levels of glucocorticoids may induce proinflammatory cytokine expression. 69 Furthermore, cytokines released from microglia inhibit neurogenesis and promote neural apoptosis, 70, 71 and these processes have been implicated in the neuroprogression associated with PTSD and related disorders. 72 Sleep disturbance, a common symptom of PTSD, is another possible mechanism for the link between PTSD, OXS, and INF. Sleep is essential to cellular processes in the brain involved in detoxification and restoration. 73 Its restorative properties are based on the reduction of neural activity (including glucose metabolism and oxidation processes), which allows antioxidant and anti-inflammatory processes to catch up with the metabolic by-products of the waking hours. In the domain of OXS, clinical studies have found increased levels of OXS markers following laboratory-induced sleep deprivation 74 and in patients with primary insomnia. 75 Additional support comes from animal studies that have found evidence of OXS in the hippocampus, cortex, and amygdala after sleep deprivation 76 and also found that these effects are blocked with antioxidant agents. 77 Similarly, sleep deprivation has been shown to cause increases in levels of proinflammatory molecules such as tumor necrosis factor-alspha (TFN-alpha), the interleukins (e.g., IL-1 beta, IL-6) and CRP. 78 Chronic sleep loss may induce blood-brain barrier disruption via the regulatory effect of inflammatory molecules on tight junction proteins. 79 Furthermore, a recent study of military personnel who were diagnosed with insomnia and underwent cognitivebehavioral therapy for insomnia showed that individuals who responded to treatment with improved sleep showed Chronic PTSD reduced expression of the inflammatory cytokines IL-1 beta, IL-6, IL-8, and IL-13. These changes were also associated with a reduction in depression symptoms. 80 
CONSEQUENCES OF PTSD-RELATED OXIDATIVE STRESS AND INFLAMMATION: NEUROPROGRESSION AND ACCELERATED AGING
Imaging studies have linked PTSD to reduced volume or thickness of the anterior cingulate cortex, left temporal pole/ middle temporal gyrus, and ventromedial prefrontal cortex. 81 Similarly, in the subcortex, a recent meta-analysis supported the association between PTSD and smaller volumes in the hippocampus (36 studies; n = 1623) and amygdala (14 studies; n = 682). 82 The functional significance of these differences, however, remains unclear, and it also remains unknown whether these differences reflect preexisting vulnerabilities, consequences of trauma exposure, signs of neuroprogression, or some combination. One possibility suggested by the foregoing evidence for the effects of chronic OXS and neuroinflammation on neural integrityfrom in vitro studies, animal models, and the study of other neurodegenerative disorders-is that observed differences in brain morphology are primarily a consequence, as opposed to a cause, of PTSD. That said, the types of longitudinal clinical neuroimaging studies that would be necessary to provide more definitive answers to these questions have yet to be completed.
A related line of recent research suggests that PTSD is also associated with accelerated cellular aging. One paradigm for this type of investigation makes use of epigenetic indices of cellular age derived from genome-wide DNA methylation algorithms (DNAm) that are highly correlated with chronological age (rs = .96; 1,2). Investigators have recently begun to apply these algorithms to examine factors that contribute to accelerated aging and have found accelerated DNAm age to be associated with various age-related health conditions and PTSD. For example, Wolf and colleagues 83 examined associations between PTSD, DNAm age, and measures of neural integrity in a sample of veterans with a high prevalence of PTSD and found that advanced DNAm age was associated with decline in the microstructural integrity of the genu of the corpus callosum, a region important for communication across the prefrontal cortices. Mediation analyses further showed that through this neuronal deficit, accelerated DNAm age was associated with poorer performance on tests of executive function and working memory. Similarly, evidence from epidemiological studies suggests that accelerated DNAm age estimates are associated with mortality such that every five-year increase in DNAm age beyond chronological age is associated with 11%-21% increased odds of all-cause mortality. 84 Though the biological mechanisms linking PTSD to accelerated aging remain to be identified, OXS and inflammatory processes are strong candidates for future investigation.
MAGNETIC RESONANCE SPECTROSCOPY NEUROIMAGING OF OXIDATIVE STRESS AND INFLAMMATION
Recent advances in clinical MRS technology now make it possible to visualize in vivo concentrations of OXS and INFrelated molecules in the brain. Using a standard MR scanner, MRS acquires a spectrum of various neurometabolites, or brain chemicals, from a single cubic region of interest (ROI). Each chemical has distinct resonance frequencies that can be identified by their chemical shifts and are indicative of the concentration of that metabolite within the ROI. The metabolites that MRS visualizes exist in close mechanistic proximity to the genes that regulate them. By virtue of this characteristic, when MRS parameters are analyzed in relationship to molecular genetic data, there is unprecedented potential to gain insight into the biological pathways and genetic sources of individual differences that moderate the effects of traumatic stress on neural health and function. Furthermore, investigators have also suggested that MRS can be used to detect the precursors of neuroprogression before it can be detected through standard approaches to structural morphology.
85 Table 3 provides a summary of the 22 MRS studies of PTSD that we located for this review. The most commonly studied regions have been the hippocampus and anterior cingulate cortex, with the majority of focusing on N-acetyl aspartate (NAA), creatine (or the NAA/creatine ratio), glutamate, or gamma-aminobutyric acid (GABA).
NAA is an amino acid that is synthesized in neurons and transported along axons. 109 It is considered a marker of neuronal viability, and depleted levels are commonly associated with neuronal loss. Reduced concentrations of this molecule has been the most reliable finding across PTSD studies, particularly within the hippocampus and the anterior cingulate (for a meta-analysis, see Karl & Werner [2010] ). 85 Though the underlying mechanism for reduced neuronal density and viability is not clear, preliminary evidence suggests that it may be due to downregulation of brain-derived neurotrophic factor mRNA 110 or glutamate excitotoxicity.
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Glutamate is the primary excitatory neurotransmitter in the cortex. Its coupling with glutamine is essential to normal brain function. Differentiating glutamate from glutamine using MRS has historically been challenging because the resonances of the two molecules are strongly coupled and overlap with each other in the proton spectrum. As a result, conventional one-dimensional MRS studies can measure only their combined resonances, termed Glx. As shown in Table 3 , previous studies of Glx in PTSD samples have yielded mixed results, with several studies finding elevated levels of Glx in the cortex and hippocampus, and others showing reduced Glx in the anterior cingulate cortex. More recent, twodimensional methods and higher field strength scanners now make it possible to disaggregate the signature of these two molecules. Using that approach, Rosso and colleagues 108 examined glutamate metabolism in the hippocampus and found elevated glutamate in the right hippocampus of PTSD patients and lower NAA on both sides, suggesting that lower NAA co-occurs with excess glutamate. GABA is the chief inhibitory neurotransmitter in the nervous system. Its actions are mediated by two classes of receptors (GABA A and GABA B ). GABA A receptors are targets of many anxiolytic, anticonvulsant, and sedative/hypnotic drugs and have been studied extensively in relationship to mechanisms of fear and anxiety. Previous MRS studies have found reduced levels of GABA in various brain regions involved in emotional processes in patients with anxiety disorders. PTSD studies conducted to date, however, have yielded mixed results ( Table 3 ). Given that the GABA A receptor is modulated by OXS-related mechanisms 110 and that GABA A receptor responses are potentiated in the presence of GSH and inhibited by oxidized GSH, 111 future studies examining GABA and GSH levels simultaneously could shed new light on the interplay between OXS and mechanisms of fear and anxiety.
Myo-inositol (mI) is present primarily in the intercellular solution of glial cells that are activated during INF, with these changes accompanied by increased volume of mI in the cell. 112 MRS studies measuring mI in conjunction with NAA have provided evidence for its role of INF (indexed by mI) and loss of neuronal integrity (indexed by NAA) in a variety of psychiatric and neurodegenerative conditions. 113, 114 In addition, consistent with the hypothesis that sleep disturbance potentiates OXS and INF, one noteworthy MRS study of healthy older adults found a strong positive correlation between poorer self-reported sleep quality and mI in the hippocampus (r = .42). 115 For this review, we were able to locate five MRS studies that have examined mI in samples of individuals with PTSD. Results were mixed, with one study reporting positive associations between mI concentrations and a diagnosis of PTSD, 94 one finding reduced mI in PTSD patients with comorbid alcohol use disorders, and three finding no significant differences between PTSD cases and controls. 99, 106, 107 Unfortunately, the interpretation of these findings is complicated by the small size of the samples that have been studied, substantial differences between studies in sample characteristics, differences in ROIs examined, and varying methods of computing mI concentrations. Additional studies are needed to clarify the nature of the relationship of mI levels to PTSD.
Thus far, the metabolites discussed have been shown to play a role in neuroinflammation, but none directly measures OXS. Recent technical developments, however, permit visualization of the brain's most abundant antioxidant molecule: glutathione. GSH is biologically synthesized through enzymatic reactions; it exerts its antioxidant effects by detoxifying ROS; and the maintenance of adequate levels of GSH is essential for preventing oxidative damage to the brain. To maintain redox homeostasis, GSH increases in response to elevated ROS. When OXS becomes prolonged, however, and cellular mechanisms fail to counteract these processes, the amount of free GSH becomes depleted, leading to irreversible cell degeneration and cell death. 9 Depleted GSH has been observed in post-mortem prefrontal cortex tissue from patients with a variety of psychiatric and neurodegenerative diseases. 116 Historically, its detection in the brain has been technically challenging because of its overlap with many other resonances and its low concentration. New spectral-editing methods and more advanced post-processing methods, however, allow for the direct measurement of this important metabolite via MRS. To our knowledge, only one published study has used MRS to examine GSH concentrations in PTSD patients. 19 In that study Michels and colleagues 19 measured GSH concentrations in the dorsolateral prefrontal cortex and anterior cingulate cortex of PTSD patients (n = 12) and controls (n = 17). Analyses revealed GSH concentrations to be 23% 
IMPLICATIONS FOR THE DEVELOPMENT OF NOVEL THERAPEUTICS
The foregoing review points to the potential value of research and development on antioxidant or anti-inflammatory compounds in the treatment of PTSD. The use of antioxidant supplements is supported by evidence from in vitro studies examining antioxidant efficacy, nutrition studies of antioxidantrich diets (e.g., in reducing risk for Alzheimer's disease 118 ), and animal studies demonstrating the use of antioxidant supplements to reduce OXS. 119 Some clinical studies have supported the use of antioxidant compounds. For example, Dysken and colleagues 120 showed that vitamin E, compared to placebo, significantly reduced the rate of functional decline in veterans with mild to moderate Alzheimer's disease and decreased caregiver burden. Unfortunately, many human clinical trials of antioxidant therapeutics have been less successful, with the majority of studies showing minimal or inconclusive benefits. 121 One possible explanation for the lack of more promising findings of antioxidant therapeutics in clinical trials is that that not all patients benefit equally from antioxidant therapeutics, as there are substantial genetic individual differences in OXS reactivity. Another consideration is that, although OXS damage may be limited to specific brain regions, cells types, or cell membranes, most of the antioxidant therapies are global, with poor target specificity. Therefore, an antioxidant compound that is more targeted may be better suited for the study of antioxidant therapeutics. One such compound is the antioxidant SS31, which targets the mitochondria and has been shown to protect neurons from neurotoxins. 122 Similarly, L-carnitine, which is a free-radical scavenger, 123 has been found to reduce OXS damage and improve outcomes in patients with mood and neurodegenerative disorders. 124, 125 Another relevant compound is N-acetylcysteine, a liposome encapsulated with GSH that can cross the bloodbrain barrier and also promote GSH levels in the brain. 116 N-acetylcysteine has shown positive clinical outcomes in disorders such as Alzheimer's disease, schizophrenia, and depression, and also has been shown to protect against OXS. 126 Research on the development of anti-inflammatory treatments for PTSD to date has been limited to animal models. For example, administration of ibuprofen to rats subjected to a substantial stressor showed reduced anxious behavior and reduced expression of inflammatory markers in the hippocampus compared to rats not administered the drug. 127 Similarly, rats fed a diet enriched for curcumin, a component in the turmeric spice with anti-inflammatory properties, showed reduced consolidation of fear-related memories during a conditioning paradigm and also reduced reconsolidation of an existing fear memory, 128 suggesting a possible role for anti-inflammatories in fear-memory formation and retention. In a separate study, rats fed a diet enriched with blueberries, which also have anti-inflammatory properties, and subjected to a trauma-like paradigm (including repeated and extended exposure to a cat) showed reduced anxiety behavior and decreased expression of a number of inflammatory proteins in the prefrontal cortex. 129 Though human studies have yet to be conducted, a substantial number of individuals with PTSD are likely to be regular users of anti-inflammatories, given the comorbidity between PTSD and chronic pain 130 and the common recommendation for use of prescription and over-thecounter anti-inflammatories to treat pain-related conditions. 131 This suggests that it may be possible to make use of existing archived or medical record data to begin to examine whether and how anti-inflammatory use is related to PTSD severity.
In contrast to the nascent research concerning antiinflammatory compounds and PTSD, the literature regarding anti-inflammatory agents and neurodegeneration is much more developed. Polyphenols (e.g., curcumin and other compounds founds in vegetables, spices, and fruits) exert both antioxidant and anti-inflammatory effects, and are associated with decreased risk for dementia and Alzheimer's disease (see Molino et al., 132 Davinelli et al., 133 and Venigalla et al. 134 ). Beyond pharmacological treatment to reduce INF and neuroinflammation, exercise may also lead to reduced INF and improved neuronal health (see Bertram et al., 135 and Svensson et al. 136 ), suggesting a potential alternative behavioral approach to moderating INF. In addition, many drugs that exert direct effects on homeostatic and metabolic functions, OXS processes, and the glucocorticoid system may have downstream effects on inflammatory parameters and thereby may play a role in reducing peripheral and neuroinflammation.
CONCLUSION
We have reviewed evidence from in vitro studies, animal models, and clinical, neuroimaging, and genetic studies consistent with the hypothesis that chronic PTSD is associated with elevated systemic OXS and INF. Many of the clinical findings, however, have been based on peripheral biomarkers that are, at best, indirect indicators of OXS and INF in the brain. Post-mortem PTSD brain tissue studies are notably absent from this literature but could provide important insights into the presence and location of inflammatory markers and oxidative damage in the brain and would offer the opportunity to cross-validate findings across tissue, neuroimaging, and blood-based investigations. Given that OXS and INF are involved both in normal aging and a wide variety of diseases, it is untenable to conceptualize these processes as specific to stress-related disorders or PTSD. Rather, these processes are best approached as ubiquitous disease phenomena that are potentiated by traumatic stress, chronic PTSD, and related conditions. As such, markers of these phenomena remain potentially fruitful candidates for future PTSD-related biomarker identification and treatment development.
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